Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques.
COVID-19
SARS-CoV-2
immunogenicity
live oral vaccine
protective efficacy
Journal
Journal of virology
ISSN: 1098-5514
Titre abrégé: J Virol
Pays: United States
ID NLM: 0113724
Informations de publication
Date de publication:
26 01 2022
26 01 2022
Historique:
pubmed:
28
10
2021
medline:
8
2
2022
entrez:
27
10
2021
Statut:
ppublish
Résumé
Live oral vaccines have been explored for their protective efficacy against respiratory viruses, particularly for adenovirus serotypes 4 and 7. The potential of a live oral vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), however, remains unclear. In this study, we assessed the immunogenicity of live SARS-CoV-2 delivered to the gastrointestinal tract in rhesus macaques and its protective efficacy against intranasal and intratracheal SARS-CoV-2 challenge. Postpyloric administration of SARS-CoV-2 by esophagogastroduodenoscopy resulted in limited virus replication in the gastrointestinal tract and minimal to no induction of mucosal antibody titers in rectal swabs, nasal swabs, and bronchoalveolar lavage fluid. Low levels of serum neutralizing antibodies were induced and correlated with modestly diminished viral loads in nasal swabs and bronchoalveolar lavage fluid following intranasal and intratracheal SARS-CoV-2 challenge. Overall, our data show that postpyloric inoculation of live SARS-CoV-2 is weakly immunogenic and confers partial protection against respiratory SARS-CoV-2 challenge in rhesus macaques.
Identifiants
pubmed: 34705557
doi: 10.1128/JVI.01599-21
pmc: PMC8791250
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
COVID-19 Vaccines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0159921Subventions
Organisme : Henry Jackson Foundation
ID : 2018-CHEDA-001-948100
Organisme : Musk Foundation
Organisme : Ragon Institute of MGH, MIT and Harvard (Ragon Institute)
Références
Nat Rev Gastroenterol Hepatol. 2021 Apr;18(4):269-283
pubmed: 33589829
Nat Med. 2005 Apr;11(4 Suppl):S45-53
pubmed: 15812489
Nature. 2020 May;581(7809):465-469
pubmed: 32235945
Lancet. 2006 Jul 22;368(9532):323-32
pubmed: 16860702
Vaccine. 2013 Jul 11;31(32):3236-43
pubmed: 23707160
Gut. 2020 Jun;69(6):1143-1144
pubmed: 32139552
Cell Host Microbe. 2020 Sep 9;28(3):364-370
pubmed: 32798444
Cell Rep Med. 2020 Oct 20;1(7):100121
pubmed: 32984855
Gastroenterology. 2020 May;158(6):1831-1833.e3
pubmed: 32142773
J Clin Diagn Res. 2014 Jul;8(7):ZC56-60
pubmed: 25177640
Gastroenterology. 2021 Apr;160(5):1647-1661
pubmed: 33307034
Mil Med. 1995 Jun;160(6):300-4
pubmed: 7659229
Sci Immunol. 2020 May 13;5(47):
pubmed: 32404436
Nat Rev Immunol. 2006 Feb;6(2):148-58
pubmed: 16491139
Vaccine. 2016 Aug 31;34(38):4558-4564
pubmed: 27475474
J Infect Dis. 1971 Aug;124(2):148-54
pubmed: 4330997
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
Vaccine. 2013 Jun 19;31(28):2963-71
pubmed: 23623865
Adv Drug Deliv Rev. 2017 May 15;114:116-131
pubmed: 28438674
Future Microbiol. 2015;10(5):791-808
pubmed: 25824845
Vaccine. 2008 Jun 2;26(23):2890-8
pubmed: 18448211
Science. 2020 May 29;368(6494):948-950
pubmed: 32393526
Nature. 2020 Oct;586(7830):583-588
pubmed: 32731257
Am J Epidemiol. 1971 Aug;94(2):142-6
pubmed: 4327997
Science. 2020 Aug 14;369(6505):806-811
pubmed: 32434945
Science. 2020 Aug 14;369(6505):812-817
pubmed: 32434946
Am J Public Health Nations Health. 1957 Jul;47(7):841-7
pubmed: 13435388
Vaccine. 2019 Nov 28;37(50):7328-7335
pubmed: 28396207
Curr Opin Biotechnol. 2007 Dec;18(6):546-56
pubmed: 18063357
J Virol. 2021 Jan 20;:
pubmed: 33472939
Nat Rev Immunol. 2014 Oct;14(10):667-85
pubmed: 25234148
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Science. 2020 Jul 3;369(6499):50-54
pubmed: 32358202
Vaccines (Basel). 2020 Jul 23;8(3):
pubmed: 32718082
J Virol. 2021 Mar 16;:
pubmed: 33727331